Ruitu Biotech develops AI-powered medical diagnostic equipment and systems, centered on its next-generation DeepCell platform. The company offers end-to-end, fully automated testing products covering eight specimen categories: blood, vaginal discharge, semen, chromosomes, urine, feces, sputum, and tissue. Its solutions target clinical laboratories with a goal of delivering intelligent, system-level diagnostic workflows. Recent financing will fund core product production, commercialization, and iterative R&D. The company positions itself as a provider of full-specimen, full-process, fully automated and intelligent testing products for clinical medicine. No operating metrics were disclosed in the article.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Dec 2023